pharmacoresistant

pharmacoresistant

(for″mă-kō-ri-zis′tănt) [pharmaco- + resistant]
Not easily treated with drugs; drug resistant. The term is used to describe refractory infections or tumors.
pharmacoresistance (-zis′tăns)
Mentioned in ?
References in periodicals archive ?
Genetic association study of the HLA class II alleles DRBl, DQAl, and DQBl in patients with pharmacoresistant temporal lobe epilepsy associated with mesial hippocampal sclerosis.
Aim: To evaluate the value of vagal nerve stimulation (VNS) in improving the quality of life, seizure frequency and mood in children with pharmacoresistant epilepsy.
Initially, a ketogenic diet proved to be an effective therapy in pharmacoresistant epilepsy.
Vagus nerve stimulation in the treatment of pharmacoresistant depression.
In the case of a pharmacoresistant epilepsy, a hemispherectomy is a treatment of choice with a success rate of 85% in carefully selected cases.
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, openlabel study.
found that the correlation of multichannel EEG decreased during the first half of the seizures while it increased before the seizure termination in patients with pharmacoresistant focal epilepsy [33].
A 2-year-old Caucasian boy had suffered severe B streptococcal meningoencephalitis at the age of 2 months, with resultant severe global developmental delay (DQ < 25), microcephaly, generalized hypotonia with tetraparesis, and pharmacoresistant epilepsy.
The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country.
EpiMiRNA brings together experts on the neurobiology of miRNAs with the leading researchers working on miRNAs in epilepsy, epilepsy geneticists, leaders in miRNA-target detection, proteomics, and systems biology with research-intensive SMEs pursuing miRNA therapeutics and treatments for pharmacoresistant epilepsy.
Parenchymal lesions in pharmacoresistant temporal lobe epilepsy: dual and multiple pathology.